glp-1/gip receptor agonists How May GIP Enhance the Therapeutic Efficacy of GLP-1? Major physiological roles of GLP-1

The oral formulation of semaglutide (Rybelsus) provides an alternative for patients with needle aversion, though it requires specific administration instructionstaken on an empty stomach with no more than 4 ounces of water, at least 30 minutes before any food, beverage, or other oral medications, and swallowed whole

Over 68 weeks, with a starting dose of 2 mg escalated every 4 weeks: 9 mg dose: 26.4% average body weight reduction (29.1 kg / 64.2 lbs) 12 mg dose: 28.7% average body weight reduction (32.3 kg / 71.2 lbs) Placebo: 2.1% average body weight reduction The milestone achievements tell an even more compelling story

Mounjaro (tirzepatide): Once-weekly injectable

In obesity treatment, especially among patients without prior experience with injectable drugs, there may be greater resistance or hesitation

The aim is to alter the cellular physiology of these specific cell subtypes by the action of the effector molecule while simultaneously capitalizing on the therapeutic benefits of the GLP-1 targeting molecule